エルロチニブ (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "エルロチニブ" in Japanese language version.

refsWebsite
Global rank Japanese rank
4th place
24th place
447th place
1,043rd place
low place
5,554th place
1,684th place
6,245th place
low place
low place
2nd place
6th place
5th place
19th place

cancer.gov

chugai-pharm.co.jp

doi.org

fda.gov

haigan.gr.jp

nih.gov

pubmed.ncbi.nlm.nih.gov

  • Pao W, Miller V, Zakowski M, et al. "EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib." Proceedings of the National Academy of Sciences of the United States of America, 101, 2004, 13306-13311. PMID 15329413
  • Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. "Erlotinib in previously treated non-small-cell lung cancer." NEJM., 353, 2005, p.p. 123-132. PMID 16014882
  • Comis RL. "The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer." Oncologist, 10, 2005, p.p. 467-470. PMID 16079313
  • Thatcher N, Chang A, Parikh P, et al. "Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer (Iressa Survival Evaluation in Lung Cancer; ISEL)." Lancet, 366, 2005, p.p. 1527-1537. PMID 16257339
  • Moore, Malcolm J.; Goldstein, David; Hamm, John; Figer, Arie; Hecht, Joel R.; Gallinger, Steven; Au, Heather J.; Murawa, Pawel et al. (2007-05-20). “Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group”. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 25 (15): 1960–1966. doi:10.1200/JCO.2006.07.9525. ISSN 1527-7755. PMID 17452677. https://www.ncbi.nlm.nih.gov/pubmed/17452677. 

ncbi.nlm.nih.gov

worldcat.org

search.worldcat.org